Podcast Index
Parcourez les podcasts par catégorie, ouvrez les épisodes récents et téléchargez l’audio pour l’écouter hors ligne.
Oncology for the Inquisitive Mind
Michael Fernando and Josh Hurwitz
Dialoghi
teisasa
IS PHARMACOLOGY DIFFICULT®️ Podcast
Dr Radhika Vijay
The Kings Code Podcast
Tate
Mindset Reloaded - Brian Tracy Motivation Daily
Motiv
The Broadcasting Seeds Podcast
Bennett Tanton
Fluent Fiction - Danish
FluentFiction.org
Fluent Fiction - Hebrew
FluentFiction.org
Fluent Fiction - Serbian
FluentFiction.org
FluentFiction - Finnish
FluentFiction.org
Fluent Fiction - Russian
FluentFiction.org
Fluent Fiction - Catalan
FluentFiction.org
Fluent Fiction - Norwegian
FluentFiction.org
Fluent Fiction - Polish
FluentFiction.org
Fluent Fiction - Spanish
FluentFiction.org
Fluent Fiction - Dutch
FluentFiction.org
Fluent Fiction - Korean
FluentFiction.org
Fluent Fiction - German
FluentFiction.org
Fluent Fiction - French
FluentFiction.org
Fluent Fiction - Italian
FluentFiction.org
Fluent Fiction - Mandarin Chinese
FluentFiction.org
Fluent Fiction - Japanese
FluentFiction.org
Fluent Fiction - Hungarian
FluentFiction.org
Fluent Fiction - Swedish
FluentFiction.org
Fluent Fiction - Vietnamese
FluentFiction.org
Fluent Fiction - Greek
FluentFiction.org
Fluent Fiction - Hindi
FluentFiction.org
Fluent Fiction - Ukrainian
FluentFiction.org
FluentFiction - Afrikaans
FluentFiction.org
FluentFiction - Romanian
FluentFiction.org
FluentFiction - Croatian
FluentFiction.org
FluentFiction - Czech
FluentFiction.org
FluentFiction - Bulgarian
FluentFiction.org
FluentFiction - Latvian
FluentFiction.org
FluentFiction - Indonesian
FluentFiction.org
FluentFiction - Estonian
FluentFiction.org
FluentFiction - Slovak
FluentFiction.org
Éducation
Michael Fernando and Josh Hurwitz
This week, Josh and Michael's ASCO 2026 coverage looks at "Agents of the Future", trials of intrigue, promise and potential beyond its status. This episode also sheds light on more orphan status cancers like head and nec...
ASCO 2026 is done, and Michael and Josh have created a marathon episode for you all. This week we cover "Agents of the Present", where we summarise all the important trials with updates, overall survival and progression-...
This week, we take a quick trip to Stockholm, Sweden, where ESTRO (European Society for Radiotherapy and Oncology) took place several weeks ago. A/Prof Steven David digs deep into the latest updates in the breast cancer ...
This episode tells the story of how one man, Jake Messier, who is living with metastatic male breast cancer, is challenging the stigma surrounding this disease, which affects 1% of all breast cancer patients. It's an imp...
This week, we take a "back to the future" look at the early-stage pancreatic cancer phase, a relatively stagnant area in terms of pivotal trials. The two trials are the ESPAC4 trial, which examines doublet chemotherapy i...
Today, we accidentally skipped early pancreatic cancer and jumped straight to advanced pancreatic cancer. It was a sombre episode, with clinicians and advocates screaming for better treatment options for this cancer. Whi...
On today's episode, Josh and Michael "advance" in their ongoing GI journey, as Michael continuously insists on saying, to discuss advanced gastric and GOJ cancer. Historically, an orphan disease with a very poor prognosi...
This week, as we enter our 200th episode, Michael and Josh continue their journey through the alimentary canal, exploring the world of stomach cancer. Gastric cancer has been notoriously difficult to treat, with a thirty...
Good therapeutic options for metastatic colorectal cancer are limited after the fluoropyrimidine-based options are exhausted. This week, we explore the role of trifluridine-tipiracil (Lonsurf) and bevacizumab (VEGF inhib...
Today's episode, like several of the greatest cult classics, comes a bit earlier than anticipated. Before we wrap up our epic recap of the colorectal space, we will give you a little taster of our UGI series with a look ...
Metastatic Colorectal Cancer has a dearth of targetable mutations that have effective outcomes. This week, Michael and Josh see whether the wonder drug (trastruzumab deruxtecan) works in HER2-expressing colorectal cancer...
UPDATED WITH CORRECT AUDIOWhile Michael daydreams of getting a haircut, this week's topics are slightly more conventional as we explore the role of more targeted agents in metastatic colorectal cancer. KRAS and BRAF muta...
Historically, colorectal cancer treatment has been fairly standard, but this has shifted over the past decade with the introduction of targeted therapies. This week, our focus is on patients with microsatellite instabili...
Metastatic colorectal cancer is one of the leading causes of cancer-related deaths and among the most common types of cancer worldwide. Chemotherapy remains the main treatment, but the question is: how can we make it mor...
Professor Jonathan E. Rosenberg, MD, serves as the Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Centre (MSKCC). He is a prolific researcher and author, holding multiple titles including ...
The DYNAMIC duo are back, with Michael climbing the "Everest" of oncology and exploring the role of CTDNA in stage two colorectal cancer. Josh has the easier job of exploring neoadjuvant immunotherapy (ipilimumab and niv...
This week, we explore early colorectal cancer. Maybe it’s just this week, but there were plenty of “IDEAS” around. Michael highlights the importance of choosing an appropriate adjuvant regimen, whether that be FOLFOX or ...
Mesothelioma can strike at any time, but it most commonly affects those in their 70s, with cases continuing well into the 2030s. The time from exposure to diagnosis can be up to 60 years. This week, we explore treatment ...
This week, we return to our regular programming with a back-to-basics exploration of extensive small-cell lung cancer. A notorious killer and an aggressive type of lung cancer, it has seen new treatments developed at a f...
Today, our guest is a transformative figure in bowel cancer treatment. Professor Jenny Seligmann, a Consultant Medical Oncologist and Professor of Gastrointestinal and Translational Oncology at the University of Leeds, i...
Remplissez le formulaire ci-dessous. Veillez à sélectionner à la fois Pays et Genres.
Envoyez-nous un message ci-dessous. Nous vous répondrons dans les 24 heures.